Bryn Roberts - Roche

Digging into data to advance new cancer drugs

Bryn Roberts
Global head of informatics in pharma research and early development, Roche

A massive surge of data from genomic studies has flooded the scientific landscape, including information on new potential genetic drivers of cancer. As Roche ($RHHBY), the world's largest cancer drug provider, ventures to extract knowledge from the data deluge, scientists rely heavily on advanced computational tools.

So Bryn Roberts, Roche's global informatics head, has a big job as the man in charge of equipping the company's pharma researchers with said tools--and not just for those focused on oncology but other disease areas as well.

Last year Roberts was in the spotlight for his leading role in providing informatics support for Roche's genomics work, involving a major cancer gene sequencing effort and analyzing hundreds of terabytes of data, Reuters reported. It's also stockpiling data from lab experiments to test compounds against certain cancer cells. 

These studies hold high strategic value for the company because every other biopharma company wants to advance new genetic drugs against cancer, and lots of pharma rivals would love to knock Roche from the No. 1 spot. Yet only companies that make smart use of data from inside and outside of their labs have a shot to succeed.

Roberts has pushed for development of informatics tools to bring Roche scientists data from experiments of their colleagues and the rest of the research world. And he has talked up advances in cloud computing to support collaboration in the industry to solve big problems.

"The scale of the problem means the solution will be on an international collaborative scale," Roberts told Reuters.

For more:
Roche seeks advances in cloud computing for cancer drug research
Roche informatics guru tackles complex data


Bryn Roberts - Roche

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.